Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer

-Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,
gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease A
confirmed positive urine drug test. History of regular alcohol consumption exceeding 14
drinks/week (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5
ounces (45 mL) of hard liquor) within 6 months of screening.

Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes
per day or 2 chews of tobacco per day.

Screening supine blood pressure greater or equal than140 mm Hg (systolic) or 90 mm Hg
(diastolic), following at least 5 minutes of supine rest. If blood. Screening supine
12-lead ECG demonstrating QTc >450 msec or a QRS interval >120 msec.

Subjects with abnormalities in clinical laboratory tests at screening, as assessed by the
study-specific laboratory and confirmed by a single repeat, if deemed necessary.

Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5
half-lives (whichever is longer) prior to the first dose of study treatment. Herbal
supplements must be discontinued at least 28 days prior to the first dose of
investigational product.

Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within
56 days prior to dosing.

History of sensitivity to heparin or heparin-induced thrombocytopenia. Unwilling or unable
to comply with the Lifestyle Requirements described in the protocol.

Subjects with severe claustrophobia impacting ability to perform the baseline MRI or PET
scans.

Fulfillment of any of the MRI contraindications on the standard radiography screening
questionnaire (metal implants, devices, paramagnetic objects contained within the body and
excessive or metal-containing tattoos). Any person unable to lie still within the
environment of the MRI and PET scanners for the required period to acquire images.

Subjects with any anatomical abnormality in the head that would either preclude or tend to
confound the analysis of study data, including any clinically significant abnormal findings
from MRI of the head.

Subjects with history of prior radiation exposure for research purposes (eg, x-ray,
computer tomography scans, or PET research study(ies)) within the past year Subjects with
insufficient arterial patency as determined by Allen's test. Any condition possibly
affecting the placement of an intravenous drug administration line, such as poor vein
rating as per PCRU procedures. History of sensitivity to local anesthetics likely to be
used in the placement of the arterial line.

History of human immunodeficiency virus (HIV), hepatitis B or C; positive testing for HIV,
hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb) and hepatitis C
antibody (HCVAb). Male subjects who are unwilling or unable to use a highly effective
method of contraception as outlined in this protocol for the duration of the study and for
at least 28 days after the last dose of investigational product